Chief Commercial Officer · Pacira BioSciences, Inc. (PCRX)

Dennis McLoughlin

FY2018 is the first fiscal year CompBrief holds for Dennis McLoughlin as a named executive officer of Pacira BioSciences; the record below is that year, complete. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2018

$2,527,714

Salary $319,231Stock awards $302,006Bonus $200,000

2nd of 5 named executive officers at Pacira BioSciences by FY2018 total.

5 named officers on file for Pacira BioSciences, FY2018

Dennis McLoughlin’s pay file — $29

  • 1 fiscal year of pay, line by line
  • 4 equity grants, each cited to its filing
  • PCRX’s disclosed peer group of 17 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Pacira BioSciences’s whole pay program stands against its peers

  • Pacira BioSciences’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on PCRX→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 22, 2019 (DEF 14A).

Free

Get Dennis McLoughlin’s full pay file as a PDF — free

More than this page: up to 10 years of Dennis’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

Dennis McLoughlin compensation by year

Pacira BioSciences Summary Compensation Table · the one fiscal year held
In US dollars, as Pacira BioSciences reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2018
Salary$319,231
Bonus$200,000
Stock awards$302,006
Option awards$1,689,835
Non-equity incentive$0
Pension and deferred compensation$0
All other$16,642
Total$2,527,714

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Pacira BioSciences, Inc. DEF 14A filed April 22, 2019, accession 0001047469-19-002459, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Pacira BioSciences, Inc. filed document, accession 0001047469-19-002459. Every figure is read from that document and cited to the page and table it appears in. Filed April 22, 2019.

Equity holdings

unvested awards at FY2018 year-end
TypeUnvested unitsValue at year-endExercise price
RSU7,875$338,783—
RSU2,250$96,795—
RSU600$25,812—
RSU437$18,800—
Option20,000—$46.55
Option20,000—$33.10
Option47,250—$38.35
Option3,750—$44.20
Option6,250—$44.10
Option1,685—$41.90
Option3,000—$32.35
Option900—$40.34

Per the Outstanding Equity Awards at Fiscal Year-End table in Pacira BioSciences, Inc.'s FY2018 proxy; value at the fiscal year-end close, as the company printed it. The 12 largest of 13 award rows shown.

Pacira BioSciences’s named executive officers, FY2018

as the company reported each
Named executive officerRoleFY2018 total
David StackChief Executive Officer$5,835,918
Dennis McLoughlin · this pageChief Commercial Officer$2,527,714
Richard ScrantonChief Medical Officer$2,266,550
Kristen WilliamsChief Administrative Officer and Secretary$1,935,056
Charles Reinhart IIIChief Financial Officer$1,407,673

The full Pacira BioSciences compensation record

free company brief

This page is one person within Pacira BioSciences's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the Pacira BioSciences proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Pacira BioSciences's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Dennis McLoughlin's compensation dossier · One-time report. No refunds.